Patents by Inventor Andrew James Peat

Andrew James Peat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS
    Publication number: 20240066037
    Abstract: Provided are cathepsin inhibitor compounds and pharmaceutically acceptable salts thereof, and combinations thereof, for use in the treatment or prophylaxis of viral disease in an animal.
    Type: Application
    Filed: March 26, 2021
    Publication date: February 29, 2024
    Inventors: Sina BAVARI, Christopher D. KANE, Andrew James PEAT, Veronica SOLOVEVA
  • Formulations for intravenous administration
    Patent number: 10945947
    Abstract: The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: March 16, 2021
    Inventors: Rachel Apfelbaum, Andrew James Peat, Yoon Oh
  • FORMULATIONS FOR INTRAVENOUS ADMINISTRATION
    Publication number: 20200206129
    Abstract: The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 2, 2020
    Inventors: Rachel Apfelbaum, Andrew James Peat, Yoon Oh
  • FORMULATIONS FOR INTRAVENOUS ADMINISTRATION
    Publication number: 20180369135
    Abstract: The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.
    Type: Application
    Filed: November 30, 2016
    Publication date: December 27, 2018
    Inventors: Rachel APFELBAUM, Andrew James PEAT, Yoon OH
  • Benzofuran compounds for the treatment of hepatitis C virus infections
    Patent number: 9682999
    Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: June 20, 2017
    Assignee: Glaxo Group Limited
    Inventors: Pek Yoke Chong, John F. Miller, Andrew James Peat, John Brad Shotwell
  • Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections
    Publication number: 20150080343
    Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Inventors: Pek Yoke Chong, John F. Miller, Andrew James Peat, John Brad Shotwell
  • Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections
    Publication number: 20130237501
    Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.
    Type: Application
    Filed: August 10, 2012
    Publication date: September 12, 2013
    Applicant: Glaxo Group Limited
    Inventors: Pek Yoke Chong, John F. Miller, Andrew James Peat, John Brad Shotwell
  • Chemical compounds
    Patent number: 8304419
    Abstract: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: November 6, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Pek Yoke Chong, Andrew James Peat, Paul Richard Sebahar, Michael Youngman, Huichang Zhang
  • Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
    Patent number: 7834013
    Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 16, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, Jr.
  • CHEMICAL COMPOUNDS
    Publication number: 20100216746
    Abstract: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.
    Type: Application
    Filed: June 5, 2008
    Publication date: August 26, 2010
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: PEK Yoke Chong, Andrew James Peat, Paul Richard Sebahar, Michael Youngman, Huichang Zhang
  • AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40
    Publication number: 20090105257
    Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.
    Type: Application
    Filed: November 15, 2004
    Publication date: April 23, 2009
    Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, JR.
  • Kv2.1 antagonists
    Patent number: 6589934
    Abstract: The invention relates to methods of treatment of non insulin dependent diabetes mellitus, antagonists of the delayed rectifier potassium channel Kv2.1, methods of using and preparing the antagonists and assays for identifying such antagonists.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: July 8, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Dulce Garrido Bubacz, Iain David Dukes, Ed Williams McLean, Robert Anderson Noe, Andrew James Peat, Jerzy Ryszard Szewczyk, Stephen Andrew Thomson, Jennings Franklin Worley, III